



Office of Technology Transfer and Development  
31 Center Drive Room 4A29, MSC2479  
Bethesda, MD 20892-2479  
Michael Shmilovich, Esq., CLP  
[shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov)

August 31, 2020

Manon Ress, Union for Affordable Cancer Treatment  
James Love, Knowledge Ecology International (KEI)

IN RE: Prospective Grant of Exclusive Patent License: Immunotherapy for Relapsed/  
Refractory Diffuse Large B Cell Lymphoma to ONK Therapeutics. 85 FR 157, 49387 (August 13, 2020)

Dear Dr. Ress and Mr. Love:

Thank you for providing us with your comments regarding the aforementioned Federal Register notice.

Prior to posting notices of a proposed grant of exclusive commercialization licenses, the NIH determines that the criteria set forth in 37 CFR 404.7(a)(1)(ii-iii) have been satisfied and that the company applying is qualified both technically and financially to be granted an exclusive license to the Government's intellectual property in the field specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license. We reviewed your comments pertaining to your cited federal statutes regulations and other licensing issues and will take them into consideration.

If your organization requests more documentation, such requests should be filed under the Freedom of Information Act. The webpage for the NIH FOIA Office provides more information on filing requests <http://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office/submitted-foia-requests>.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael A. Shmilovich". The signature is fluid and cursive, with a long horizontal stroke at the end.

Michael A. Shmilovich, Esq., CLP